Specialized CRO ChanTest is a focused ion channel and GPCR CRO with long-standing experience in safety testing and screening for global pharma and biotech customers, presenting a clear value proposition for companies seeking niche nonclinical cardiac safety assessments.

Comprehensive IP The company boasts a library of validated ion channel cell lines and a broad nonclinical cardiac risk assessment service portfolio, enabling rapid project initiation and differentiated offerings for clients needing robust safety data.

Trusted Partner With a track record since 1998 and recognition as the most trusted and most used fee-for-service provider for ion channel screening in HTStec surveys, ChanTest can leverage credibility to win new engagements and renewals.

Global Reach Having served more than 300 global pharma and biotech companies, ChanTest demonstrates scalable capability and international exposure, suggesting opportunities for expanded partnerships and larger study scopes.

Growth Signals Revenue is in the one-to-ten million range, indicating opportunities to upsell larger GLP and non-GLP services, preclinical cardiac risk assessments, and expanded ion channel panels to existing customers and adjacent market players.